APLT News and Press, Applied Therapeutics Inc. From 08/07/23

2023-08-07 03:55:11 ET Summary Applied Therapeutics has experienced regular positive trial updates, frequent delays in NDA submission, and multiple dilutive stock offerings. The company's lead candidate, AT-007, showed a strong reduction in plasma galactitol but did not meet the F...

The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the safety and efficacy of AT-001 (caficrestat) in improving or preventing worsening of cardiac functional capacity in Diabetic Cardiomyopathy (DbCM); topline data from the study is expected in the fourth quarter of this year ...

Data further elucidates the pathophysiology of sorbitol toxicity, including sorbitol accumulation as the driver of disease in patient-derived motor neurons, as well as in the drosophila model and a new rat model of SORD Deficiency Clinical study data includes trial design, baseline data...

2023-05-25 07:49:29 ET The European Medicines Agency (EMA) granted orphan medicinal product designation to Applied Therapeutics' ( NASDAQ: APLT ) drug AT-007 (govorestat) to treat  Sorbitol Dehydrogenase (SORD) Deficiency. SORD Deficiency is a rare hered...

EMA Orphan Designation reflects high unmet need in SORD Deficiency and benefit of govorestat treatment in reducing toxic sorbitol levels New data published in Journal of Clinical Investigation further elucidates the molecular pathophysiology of SORD neuropathy and the role of sorbitol in ...

2023-05-12 17:04:22 ET Applied Therapeutics ( NASDAQ: APLT ) has filed for a $300M mixed shelf securities offering. The filing does not necessarily indicate that a sale has begun or will occur in the future. The offering can include common stock, preferred stock, depositar...

2023-05-11 09:02:34 ET Applied Therapeutics press release ( NASDAQ: APLT ): Q1 GAAP EPS of -$0.18 beats by $0.25 . Cash and cash equivalents and short-term investments totaled $22.9 million as of March 31, 2023, compared with $30.6 million at December 31, 2022. F...

Demonstrated Long-term Clinical Benefit of Govorestat in ACTION-Galactosemia Kids Trial Strengthened Balance Sheet with $30 Million Private Placement of Equity Phase 3 INSPIRE Trial of Govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF Trial of AT-001 in Diabeti...

2023-04-28 08:33:44 ET Hillstream BioPharma ( HILS ) -57% on pricing $2.65M equity offering . Centogene ( CNTG ) -26% receives Nasdaq non-compliance notice . Cloudflare ( NET ) -25% after Q1 earnings release . Snap ( SNAP ) -18% afte...

2023-04-27 11:12:14 ET Numerous factors must be considered as you search for penny stocks to buy in the current market. Emotions are running high, from overarching recession and inflation narratives to the potential for a stock market crash in 2023. This has led to increased volatility ...